Actively Recruiting
GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
Led by University of Alabama at Birmingham · Updated on 2026-04-09
200
Participants Needed
1
Research Sites
265 weeks
Total Duration
On this page
Sponsors
U
University of Alabama at Birmingham
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have \~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have \~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.
CONDITIONS
Official Title
GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older, with equal numbers of males and females
- Consent to provide genetic material
- Willingness to follow the study protocol
You will not qualify if you...
- Age under 18 years at screening
- Body mass index greater than 45 kg/m2
- Blood pressure higher than 140/90 mmHg
- Using more than two hypertension medications
- History of diabetes or fasting plasma glucose over 126 mg/dl or HbA1C of 6.5% or higher, or previous diabetes treatment
- Past or current cardiovascular diseases such as stroke, seizure, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia
- Pregnant or breastfeeding women, or women who can become pregnant and are not using acceptable birth control
- Estimated glomerular filtration rate below 60 ml/min/1.73 m2 or albumin creatinine ratio 30 mg/g or higher
- Liver enzyme levels (AST and ALT) more than three times the upper normal limit
- Anemia (hematocrit less than 38% for men, less than 36% for women)
- Inability to exercise on a treadmill
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Actively Recruiting
Research Team
N
Nehal Vekariya, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here